Disclosed are the unique and unexpected findings that xenon gas possesses the ability to directly inhibited amyloid beta associated toxicity, inhibit production of amyloid beta, and stimulate synthesis of soluble, free-form amyloid beta. The invention teaches the use of xenon gas, as well as various combinations of Noble Gases, for the prevention, amelioration, and treatment of Alzheimer's Disease and other pathologies associated with generation of insoluble aggregates containing amyloid beta.

Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed.

A method for determining gases proportions to obtain an inhalable medical gaseous composition consisting of a first noble gas, a second noble gas, and oxygen, in order to reach a body temperature value, including determining a proportion of first or second noble gas depending on predetermined parameters, such as the body temperature value and an inhalation temperature value, the determining further including determining, for the inhalation temperature value, two body temperature theoretical values for the first and second noble gas modeled by reference regression lines, calculating a difference between both body temperature theoretical values, calculating a difference between body temperature value and any one of the body temperature theoretical values, calculating a ratio representing proportion of first or second noble gas in the inhalable medical gaseous composition.

A method for determining gases proportions to obtain an inhalable medical gaseous composition consisting of a first noble gas, a second noble gas, and oxygen, in order to reach a body temperature value, including determining a proportion of first or second noble gas depending on predetermined parameters, such as the body temperature value and an inhalation temperature value, the determining further including determining, for the inhalation temperature value, two body temperature theoretical values for the first and second noble gas modeled by reference regression lines, calculating a difference between both body temperature theoretical values, calculating a difference between body temperature value and any one of the body temperature theoretical values, calculating a ratio representing proportion of first or second noble gas in the inhalable medical gaseous composition.

A nozzle apparatus for dispensing an adjustable combination of gas, having a nozzle outlet adjustably combined with a delivery component. The nozzle outlet may have a groove for receiving a roll pin; and an inner lumen comprising a cylindrical shaft having a diameter between 5/1000ths and 20/1000ths of an inch. The delivery component configured to receive air from the nozzle outlet, may have a first circular ambient air hole having a diameter, and a second circular ambient air hole having the same diameter as the first ambient air hole, and a removable plugging device covering the second circular ambient air hole. The delivery component may be adjustable in orientation with respect to the nozzle outlet, and may be adjustable to vary a concentration of therapeutic gas delivered to a patient.

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject.

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject.

Described here are closed-circuit breathing devices and methods for their use. In general, the closed-circuit breathing device is configured to achieve a steady-state equilibrium, whereby therapeutic gas is introduced into the breathing circuit in small, controlled volumes until a steady state concentration of the therapeutic gas is reached. During this time, the closed-circuit breathing device is operated in a true closed circuit, such that the therapeutic gas is not lost to the atmosphere. Safety measures are built into the closed-circuit breathing device so that a hypoxic mixture is not delivered to the subject. The therapeutic gas may be xenon.

Described here are closed-circuit breathing devices and methods for their use. In general, the closed-circuit breathing device is configured to achieve a steady-state equilibrium, whereby therapeutic gas is introduced into the breathing circuit in small, controlled volumes until a steady state concentration of the therapeutic gas is reached. During this time, the closed-circuit breathing device is operated in a true closed circuit, such that the therapeutic gas is not lost to the atmosphere. Safety measures are built into the closed-circuit breathing device so that a hypoxic mixture is not delivered to the subject. The therapeutic gas may be xenon.

The present invention relates to low concentration synergistic Xenon-Argon gas mixtures argon for use in a method for preventing and/or treating ischemic insults, wherein —the volume proportion of xenon is between 5 and 20%; —the volume proportion of argon is between 5 and 20%; and —the pharmaceutical composition further comprises a gas complement to reach 100% volume proportion; —the method includes comprises restoration of blood flow and the gas mixture is administered to the patient before, during, or after blood flow restoration.